Search Results for "rifampin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rifampin. Results 171 to 180 of 186 total matches.
See also: Rifadin, Rimactane

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
concentrations of istradefylline 2.5-fold and administration with rifampin, a strong CYP3A4 inducer, reduced ...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
with inhibitors of P-gp2; should not be used with the P-gp inducer rifampin; NSAIDs and other antiplatelet drugs ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
(e.g., gemfibrozil) or inducers (e.g., rifampin) should be avoided.9 The primary active metabolites ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020  (Issue 1593)
rifampin reduced ubrogepant exposure by 80%; concurrent use of ubrogepant and a strong CYP3A4 inducer ...
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-9 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
▶ Substrate of CYP3A4; inducers of 3A4, such as rifampin, can reduce efficacy of apremilast5 ▶ No adequate ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Drugs for Bacterial Infections

   
Treatment Guidelines from The Medical Letter • Jul 01, 2013  (Issue 131)
causes of prosthetic joint infection.9 Empiric treatment is discouraged. Rifampin is often added ...
The text that follows reviews some common bacterial infections and their empiric treatment pending the results of culture and susceptibility testing. The recommendations made here are based on the results of susceptibility studies, clinical trials, and the opinions of Medical Letter reviewers. Tables 1 and 2 list the usual dosages of antibacterial drugs.
Treat Guidel Med Lett. 2013 Jul;11(131):65-74 |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
, and rifampin increase clearance of valproate; an increase in the dosage of valproate is recommended ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
, such as rifampin, carbamazepine, or phenytoin, can reduce them.16 Concurrent use of methadone and other drugs ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
such as rifampin or carbamazepine can reduce its efficacy.48 DEUCRAVACITINIB — The oral tyrosine kinase 2 (TYK2 ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
of roflumilast.43 Strong inducers, such as rifampin and carbamazepine, can reduce the efficacy of roflumilast ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction